Today, MSD announced the interim results of their MOVe-OUT trial, looking at the efficacy of the oral antiviral molnupiravir in non-hospitalised adult COVID-19 patients. Dr Daria Hazuda, the Chief Scientific Officer for MSD (also known as Merck) was available to answer science journalists’ questions about the drug and the trial. She was joined by Dr Ruth McKernan, Chair at BioIndustry Association, and Eddie Gray, Chair of the UK Antivirals Taskforce.
Dr Daria Hazuda, Vice President of Infectious Disease Discovery and Chief Scientific Officer of MSD’s Exploratory Science Center in Cambridge MA
Dr Ruth McKernan, Chair at BioIndustry Association
Eddie Gray, Chair of UK Antivirals Taskforce
This Briefing was accompanied by a SMC Rapid Reaction.